2019 年第三季度报告 公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2019 年第三季度报告 1 / 23 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 23 2019 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李德福、主管会计工作负责人王鹏及会计机构负责人（会计主管人员）王鹏保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------------ ...

公司代码：600645 公司简称：中源协和 2019 年半年度报告 中源协和细胞基因工程股份有限公司 2019 年半年度报告 1 / 174 2019 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李德福、主管会计工作负责人王鹏及会计机构负责人（会计主管人员） 王鹏声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者 注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已经在本报告中详细描述了公司存在的风险因素，敬请查阅第四节"经营情况的 讨论与分析"中其他披露事项可能面对的风险。 十、 其他 □适用 √不适用 ...

证券代码：600645 证券简称：中源协和 公告编号：2019-038 中源协和细胞基因工程股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●召开时间：2019年5月9日（星期四）15：00-16:30 ●召开方式：网络方式召开 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2019年4月30 日发布了2018年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在全景网以网络方式举行"投资者网上集体接待日"活动。 二、召开时间和方式 时间：2019年5月9日（星期四）15：00-16:30 方式：网络方式召开 三、公司出席人员 公司出席本次"投资者网上集体接待日"活动的人员有：公司副董事长、总 经理李德福先生，董事、常务副总经理李旭先生，副总经理、董事会秘书杨新喆 先生，财务总监王鹏先生（如有特殊情况，出席人员会有调整）。 四、投资者参加方式 投资者可以登录" 全景·路演天下"（http://rs.p5w.net）参 ...

2019 年第一季度报告 公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2019 年第一季度报告 1 / 25 2019 年第一季度报告 í 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 25 2019 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李德福、主管会计工作负责人王鹏及会计机构负责人（会计主管人员）王鹏保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |-------------------------------------------------|------ ...

Financial Performance - The audited net profit for the parent company in 2018 was RMB 33.93 million, with accumulated undistributed profits as of December 31, 2018, amounting to -RMB 175 million[4]. - The company's operating revenue for 2018 was approximately ¥1.32 billion, a slight decrease of 0.02% compared to 2017[22]. - Net profit attributable to shareholders for 2018 was approximately ¥59.25 million, representing a significant increase of 471.58% year-over-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 1,296.39% compared to the previous year, primarily due to goodwill impairment losses[24]. - Basic earnings per share for 2018 were ¥0.15, a 400% increase from ¥0.03 in 2017[24]. - The weighted average return on equity for 2018 was 2.18%, an increase of 1.79 percentage points compared to 2017[24]. - The company generated a net cash flow from operating activities of approximately ¥130.08 million in 2018, an increase of 24.60% from the previous year[22]. - Non-recurring gains for 2018 totaled approximately ¥321.73 million, significantly higher than the previous year's gains[32]. - The company reported a net profit of approximately ¥133.48 million in Q1 2018, with a notable decline in Q4 resulting in a net loss of approximately ¥275.30 million[30]. - The company achieved a revenue of RMB 1.32 billion in the reporting period, a slight decrease of 0.02% compared to the previous year[60]. - Net profit attributable to shareholders reached RMB 59.25 million, representing a significant increase of 471.58% year-on-year, primarily due to a gain of RMB 260 million from the disposal of equity stakes in Beijing Pan Genomics and Beijing San You Li He Ze Biotechnology[60]. Asset and Investment Overview - The company's total assets at the end of 2018 were approximately ¥4.44 billion, reflecting a 0.64% increase from the previous year[22]. - The company's available-for-sale financial assets increased by 36.35% compared to the previous period, amounting to ¥307,866,380.71, which represents 6.93% of total assets[47]. - Investment properties rose by 68.78% from the previous period, totaling ¥157,750,673.03, accounting for 3.55% of total assets[47]. - The overseas assets of the company amounted to ¥481,628,032.08, representing 10.84% of total assets[47]. - The company has a total of 163,337,005.68 yuan in assets under restriction due to mortgage loans[95]. - The company has provided guarantees with joint liability for various projects, indicating a commitment to support its subsidiaries[198]. Research and Development - The company invested approximately RMB 103.3 million in research and development during the reporting period, focusing on innovation and product line expansion[37]. - R&D investment accounted for 7.82% of the company's total revenue in 2018, with over 157 R&D personnel, including 56 with master's degrees or higher[51]. - The company completed 48 stem cell research and product development projects, with 3 completed and 4 halted[82]. - The company launched the "Yuanwei Kang Disease Full Item Genetic Susceptibility Gene Detection" product, utilizing a chip developed in collaboration with Illumina, specifically designed for the East Asian population[51]. Market and Business Expansion - The company has established cell resource banks in 18 provinces, covering over 2/3 of the regions and 3/4 of the population in China, with more than 300,000 stored units accumulated over 18 years[35]. - The company has developed a national marketing network for cell detection and storage services, as well as a distributor-based network for in vitro diagnostic reagents, enhancing its sales capabilities[37]. - The company aims to leverage synergies between its business segments to mitigate risks associated with fluctuations in specific industries, ensuring sustainable growth[35]. - The company is expanding its cell storage offerings, including adult cell storage for immune and adipose stem cells, while maintaining its leadership in the newborn stem cell storage market[41]. - The company plans to enhance market penetration through new media marketing and e-commerce, leveraging its "life bank" resources[123]. Regulatory and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[4]. - The company has not proposed any profit distribution plan or capital reserve transfer plan for the 2018 fiscal year, pending approval at the annual shareholders' meeting[4]. - The company has commitments regarding share lock-up periods, with certain shareholders restricted from trading their shares for 36 months post-issuance[140]. - The company has a plan for share repurchase that is not applicable for cash dividends[137]. - The company has established a commitment to avoid and minimize related party transactions post-restructuring, ensuring fair operations at market prices[156]. Risks and Challenges - The company has detailed the risk factors it faces in the report, which can be found in the section discussing operational conditions[4]. - The company faces risks related to industry policies, technology, talent retention, quality management, and exchange rate fluctuations[130]. - In 2018, the national newborn birth rate dropped to 15.16 million, a 12% decrease from 17.23 million in 2017, impacting storage business negatively; however, the overall stem cell storage rate in China remains below 1%, indicating significant growth potential[41]. Shareholder Commitments - The company has committed to achieving a net profit of no less than 65 million yuan, 79 million yuan, and 96 million yuan for the years 2018, 2019, and 2020 respectively[145]. - The company guarantees that there will be no direct or indirect competition with Zhongyuan Xiehe and its subsidiaries in the future[145]. - The company will ensure compliance with all relevant regulations and will not exploit its shareholder position for undue benefits[148]. Legal and Audit Matters - The company is involved in significant litigation, including a case against Singapore Huide Investment Holdings for a land use rights dispute, with a judgment requiring repayment of 71.21 million yuan[171]. - The company has not faced any significant accounting errors or non-standard audit opinions during the reporting period[164]. - The audit fee for the company in 2018 was adjusted to 2.2 million yuan, including 500,000 yuan for internal control audit[168].

2018 年第三季度报告 公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2018 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 10 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李德福、主管会计工作负责人王鹏及会计机构负责人（会计主管人员）王鹏保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 21 单位：元 币种：人民币 本报告期末 上年度末 本报告期末 比上年度末 增减(%) 调整后 调整前 总资产 4,659,152,934.87 4,376,659,493.92 2,999,979 ...

2018 年半年度报告 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2018 年半年度报告 1 / 155 2018 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李德福、主管会计工作负责人王鹏及会计机构负责人（会计主管人员）王鹏声明： 保证半年度报告中财务报告的真实、准确、完整。 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投资风 险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已经在本报告中详细描述了公司存在的风险因素，敬请查阅第四节"经营情况的讨论与分析" 中其他披露事项可能面对的风险。 十、 其他 □适用 √不适用 2 ...

2018 年第一季度报告 公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2018 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 10 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上 年度末增减(%) | | | | --- | --- | --- | --- | --- | --- | | 总资产 | 3,032,917,089.85 | 2,999,979,976.43 | 1.10 | | | | 归属于上市公司股东的 | 1,576,278,763.77 | 1,509,015,295.94 | 4.46 | | | | 净资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减 | | | | | | | (%) | | | | 经营活动产生的现金流 | -27,471,358.58 ...

Financial Performance - The company's audited net profit for 2017 was -38.14 million RMB, resulting in a cumulative undistributed profit of -209 million RMB as of December 31, 2017, leading to no profit distribution to shareholders[5]. - Operating revenue for 2017 was 870.91 million RMB, representing a 3.94% increase compared to 837.90 million RMB in 2016[21]. - The net loss attributable to shareholders for 2017 was -18.46 million RMB, a decrease of 148.76% from a profit of 37.86 million RMB in 2016[22]. - The net cash flow from operating activities was 70.27 million RMB, down 51.09% from 143.67 million RMB in 2016[22]. - Total assets as of the end of 2017 were 2.99 billion RMB, a slight decrease of 0.12% from 3.00 billion RMB in 2016[22]. - The net assets attributable to shareholders decreased by 4.96% to 1.51 billion RMB from 1.59 billion RMB in 2016[22]. - Basic earnings per share decreased by 150% compared to the previous year, from 0.10 to -0.05 RMB[23]. - The weighted average return on equity dropped by 3.64 percentage points to -1.23%[23]. - The company reported a net profit of -64.43 million RMB for 2016 and -38.14 million RMB for 2017, with cumulative undistributed profits of -209 million RMB as of December 31, 2017, resulting in no profit distribution to shareholders[112]. Business Operations - The company’s main business includes cell preparation and storage services, gene testing, and sales of in vitro diagnostic reagents[32]. - The company operates under a division + direct management model, promoting independent accounting and resource integration across business units[33]. - The company achieved operating revenue of 871 million RMB, a year-on-year increase of 3.94%[47]. - The company plans to acquire 100% equity of Shanghai Aoyuan Medical Supplies Co., enhancing industry integration and core competitiveness[43]. - The company is in the process of responding to feedback from the China Securities Regulatory Commission regarding its major asset restructuring application[44]. - The company is focusing on enhancing brand awareness through various media channels and hosting events like the "Zhongyuan Xiehe Life Medicine Award" ceremony[45]. - The company plans to expand its market presence and enhance its product offerings in the coming year[55]. - The establishment of Wuhan Guanggu Zhongyuan Co. contributed to the overall revenue growth, marking a strategic expansion[56]. Research and Development - Research and development expenses rose by 43.11% to 67.11 million RMB[50]. - The company completed 16 out of 44 stem cell research and product development projects during the reporting period[63]. - The company has established a key expert group for "Stem Cell and Translational Research" to ensure the successful implementation of national key R&D projects[88]. - The company is committed to developing a wide range of testing projects and strengthening collaborations with internationally renowned institutions to provide competitive testing services[103]. - The company will continue to push forward with research and development projects and actively pursue drug approvals in both domestic and international markets[105]. Market Trends and Strategy - The global stem cell storage market is projected to reach $18.16 billion by 2018, with a compound annual growth rate (CAGR) of 21% from 2015 to 2018[92]. - The domestic stem cell storage rate is currently below 1%, indicating significant growth potential, with an estimated market size exceeding $30 billion[93]. - The approval of the first CAR-T cell therapy, Kymriah, priced at $475,000, marks a significant milestone in the commercialization of CAR-T products[96]. - The immune cell therapy sector is recognized as a key area for development, with policies supporting its growth across multiple regions in China[90]. - The company aims to secure its leading position in the immune cell field by actively applying for CAR-T drug approvals, leveraging proprietary technology and clinical application advantages[97]. Corporate Governance and Compliance - The company has established a commitment to fair and transparent dealings in any necessary related transactions with controlling shareholders[116]. - The company has confirmed that it will not require any illegal guarantees from its controlling shareholders[116]. - The company has maintained a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights[189]. - The company has no recent penalties from securities regulatory agencies, indicating compliance with regulations[183]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal regulations and the company's articles of association[190]. Shareholder and Equity Management - The company has not distributed any dividends in the last three years, with a net profit of -18.46 million RMB in 2017[112]. - The total number of ordinary shares decreased from 386,091,314 to 386,081,314 due to the repurchase and cancellation of 10,000 restricted shares[152]. - The number of shareholders increased from 41,885 to 44,607 during the reporting period[159]. - The company has a commitment to maintain a 30-month lock-up period for newly issued shares, ensuring stability in shareholding[165]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0953 million yuan[181]. Employee Management and Development - The total number of employees in the parent company and major subsidiaries is 1,981, with 931 in sales, 420 in production, and 281 in technical roles[184]. - The company has implemented a performance evaluation and compensation system for senior management, which was approved by the board of directors[181]. - A training program has been established to improve employee skills, including a special training project for mid-to-senior management called the "Blackstone Plan"[186]. - The company is focusing on enhancing its compensation and benefits system to attract and retain talent, particularly for core business personnel[185]. Financial Management and Investments - The company has made a significant equity investment of ¥12,834.40 million (100%) in Concord East China Stem Cell Gene Engineering Co., Ltd. for a 20-year term[75]. - The company holds a total of 172 authorized patents, ensuring its competitive edge in research and clinical transformation[40]. - The company has received approval for 172 patents, with 17 new patents granted in 2017[45]. - The company has implemented an employee stock ownership plan, purchasing 2,540,100 shares for a total of RMB 87,002,663.34, with an average price of approximately RMB 34.25 per share[127]. - The total investment amount during the reporting period was 263.14 million, reflecting a decrease of 37.38% compared to the previous year[74].

Financial Performance - Operating income for the first nine months was CNY 624,741,613.84, representing an increase of 11.61% year-on-year[6] - Net profit attributable to shareholders decreased by 44.06% to CNY 3,090,968.73 compared to the same period last year[6] - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of CNY -3,747,582.75, a decrease of 109.75% compared to the previous year[6] - The weighted average return on net assets decreased by 0.15 percentage points to 0.20%[6] - The company’s subsidiary Shanghai Zhicheng's net profit decreased by CNY 16,570,000 due to significant market investment and a decline in product revenue[10] - The company reported a decrease in cash flow from operating activities, impacting liquidity and operational flexibility[22] - Net profit for Q3 2017 was a loss of ¥3,369,819.03, compared to a loss of ¥7,818,162.17 in Q3 2016, indicating an improvement in financial performance[33] - The net profit attributable to the parent company for Q3 2017 was -5,296,991.91 RMB, compared to -10,469,557.23 RMB in the same period last year, showing an improvement[34] - The total comprehensive income attributable to the parent company for the first nine months of 2017 was -30,798,099.78 RMB, compared to -19,035,661.18 RMB in the previous year[34] - The total operating loss for the first nine months of 2017 was -75,036,776.86 RMB, compared to -57,795,053.04 RMB in the previous year[35] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,037,497,669.90, an increase of 1.13% compared to the end of the previous year[6] - The company's total assets increased from RMB 3.00 billion at the beginning of the year to RMB 3.04 billion by the end of the reporting period[28] - The company's total liabilities increased from RMB 1.25 billion at the beginning of the year to RMB 1.42 billion by the end of the reporting period[28] - The company's non-current assets totaled RMB 2.26 billion at the end of the reporting period, compared to RMB 2.21 billion at the beginning of the year[27] - Accounts receivable increased by 100% compared to the beginning of the year, mainly due to the receipt of bank acceptance bills by subsidiaries[13] - Prepayments increased by 162.50% compared to the beginning of the year, primarily due to prepayments for procurement and project payments during the reporting period[13] - Long-term receivables increased by 36.77% compared to the beginning of the year, mainly due to an increase in installment payments for service business[13] - Investment properties increased by 962.15% compared to the beginning of the year, as subsidiaries transferred self-owned properties to investment property accounting[13] - Long-term payables increased by 520.03% compared to the beginning of the year, mainly due to an increase in financing lease business by subsidiaries[13] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 15,109,085.41, a significant decrease of 83.33% year-on-year[6] - Net cash flow from operating activities decreased by 83.33% year-on-year, mainly due to increased salary and management expenses[16] - Cash flow from operating activities for the first nine months of 2017 was 653,355,264.86 RMB, an increase from 614,147,416.34 RMB in the same period last year[38] - The net cash flow from investment activities was -¥131,747,559.08, compared to -¥467,156,426.15 in the previous year, indicating an improvement[39] - The total cash and cash equivalents at the end of the period was ¥232,032,541.42, compared to ¥296,842,585.67 at the end of the previous year[40] - The cash outflow for investment activities was ¥855,002,324.36, compared to ¥2,270,224,580.60 in the previous year, showing a reduction in investment spending[39] Financial Expenses - Financial expenses increased by 342.68% year-on-year, primarily due to reduced interest income from time deposits and increased borrowing costs[15] - The company’s financial expenses for Q3 2017 were ¥4,209,002.08, compared to ¥615,424.44 in Q3 2016, indicating a substantial increase in financial costs[33] - The company reported a significant increase in financial expenses, totaling 6,830,766.01 RMB for the first nine months of 2017, compared to 2,538,048.97 RMB in the previous year[35] Guarantees and Repurchases - The company provided guarantees for loans totaling RMB 10 billion for related parties, with all guarantees currently in normal performance[18] - The company has provided a total guarantee amount of RMB 2 billion for the year 2017, which has not been utilized as of the report date[20] - The company plans to repurchase and cancel 2.128 million restricted stocks at a price of RMB 13.60 per share due to unmet unlocking conditions from the 2014 stock incentive plan[20]